安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Denosumab (subcutaneous route) - Side effects uses
Denosumab injection is used to treat osteoporosis (thinning of the bones) in women who have an increased risk for fractures after menopause, and osteoporosis in men It is given when other medicines cannot be used or after other medicines did not work well
- Denosumab - Wikipedia
Denosumab inhibits this maturation of osteoclasts by binding to and inhibiting RANKL Denosumab mimics the natural action of osteoprotegerin, an endogenous RANKL inhibitor, that presents with decreasing concentrations (and perhaps decreased effectiveness) in people with osteoporosis
- Prolia Injection (Denosumab): Uses Side Effects
Prolia® injection is a brand of denosumab, which treats osteoporosis Osteoporosis is a condition that weakens your bones, making them more susceptible to fractures
- Denosumab (Prolia, Jubbonti, Stoboclo): Uses, Side Effects . . . - WebMD
What is denosumab used for? Denosumab (Prolia, Jubbonti, Stoboclo) is commonly used to treat osteoporosis, a condition in which the bones are thinner, weaker, and more prone to breakage
- Denosumab Injection: MedlinePlus Drug Information
Denosumab injection is in a class of medications called RANK ligand inhibitors It works to prevent bone loss by blocking a certain receptor in the body to decrease bone breakdown
- Prolia, Xgeva (denosumab) dosing, indications, interactions, adverse . . .
Medscape - Osteoporosis, SREs, and giant cell tumor dosing for Prolia, Xgeva (denosumab), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy lactation
- Denosumab: Side Effects, Uses, Dosage, Interactions, Warnings - RxList
Denosumab is a human IgG2 monoclonal antibody used to treat bone problems that may occur with cancer that has spread (metastasized) to the bones Learn about side effects, dosages, drug interactions, and more
- Denosumab for osteoporosis - UpToDate
Denosumab is a fully human monoclonal antibody to the receptor activator of nuclear factor kappa-B ligand (RANKL), an osteoclast differentiating factor It inhibits osteoclast formation, decreases bone resorption, increases bone mineral density (BMD), and reduces the risk of fracture
|
|
|